D66 D67
Conditions
Interventions
Group 1: 8 weeks MLD treatment (2x 30 min / week) (period I),
4 week washout phase,
8 weeks without MLD treatment (period II)
Group 2: 8 weeks without additional MLD treatment (period I),
4 week washo
Sponsors
Hämophiliezentrum, Institut für Transfusionsmedizin, Medizinische Klinik III, Goethe Universitätsklinikum
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: -confirmed Haemophilie A/B diagnosis --at least one Target Joint due to recurrent bleeding events - informed consent
Exclusion criteria
Exclusion criteria: - age younger than 18 years - no Haemophilia or no target joints defined - no informed consent, incapable of giving consent -any surgery in the last 6 weeks - patients with decompensated right heart failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in subjective pain perception using the visual analog scale (VAS and hemophilia pain questionnaire) at four measuring points: Time 0: before start of period I (group A: with MLD treatment, group B: without MLD treatment) Time 1: after period I. Time 2: after wash-out phase Time point 3: after period II (group A: period without MLD treatment, group B: with MLD treatment) | — |
Secondary
| Measure | Time frame |
|---|---|
| - Change in joint mobility (ROM, Range of Motion) using a goniometer - Change in hemophilia joint score (HJHS, Haemophilia Health Joint Score) - Change in surface temperature of a target joint (infrared thermography) All measurements are taken at different times: Time 0: before the start of period I (group A: with MLD treatment, group B: without MLD treatment) Time 1: after period I. Time 2: after wash-out phase Time point 3: after period II (group A: period without MLD treatment, group B: with MLD treatment) | — |
Countries
Germany
Contacts
Public ContactWolfgang Miesbach
Hämophiliezentrum, Institut für Transfusionsmedizin, Medizinische Klinik III, Goethe Universitätsklinikum
Outcome results
None listed